360 related articles for article (PubMed ID: 25264242)
1. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
Lu C; Suri A; Shyu WC; Prakash S
Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cytochrome P450 by ethambutol in human liver microsomes.
Lee SY; Jang H; Lee JY; Kwon KI; Oh SJ; Kim SK
Toxicol Lett; 2014 Aug; 229(1):33-40. PubMed ID: 24910189
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
Bansal S; Paine MF; Unadkat JD
Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
[TBL] [Abstract][Full Text] [Related]
4. Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs.
Gao J; Wang J; Gao N; Tian X; Zhou J; Fang Y; Zhang HF; Wen Q; Jia LJ; Zou D; Qiao HL
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29054967
[TBL] [Abstract][Full Text] [Related]
5. The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk.
Lawrence SK; Nguyen D; Bowen C; Richards-Peterson L; Skordos KW
Drug Metab Dispos; 2014 Jul; 42(7):1180-90. PubMed ID: 24748562
[TBL] [Abstract][Full Text] [Related]
6. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.
Paris BL; Ogilvie BW; Scheinkoenig JA; Ndikum-Moffor F; Gibson R; Parkinson A
Drug Metab Dispos; 2009 Oct; 37(10):2045-54. PubMed ID: 19608694
[TBL] [Abstract][Full Text] [Related]
8.
Tseng E; Lin J; Strelevitz TJ; DaSilva E; Goosen TC; Obach RS
Drug Metab Dispos; 2024 Feb; ():. PubMed ID: 38408867
[TBL] [Abstract][Full Text] [Related]
9. Assessment of drug-drug interaction for silymarin.
Doehmer J; Tewes B; Klein KU; Gritzko K; Muschick H; Mengs U
Toxicol In Vitro; 2008 Apr; 22(3):610-7. PubMed ID: 18249085
[TBL] [Abstract][Full Text] [Related]
10. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6.
Bhateria M; Ramakrishna R; Puttrevu SK; Saxena AK; Bhatta RS
Chem Biol Interact; 2016 Aug; 256():257-65. PubMed ID: 27387538
[TBL] [Abstract][Full Text] [Related]
12. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities.
Dixit V; Hariparsad N; Desai P; Unadkat JD
Biopharm Drug Dispos; 2007 Jul; 28(5):257-62. PubMed ID: 17443647
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
[TBL] [Abstract][Full Text] [Related]
14. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities.
Doehmer J; Weiss G; McGregor GP; Appel K
Toxicol In Vitro; 2011 Feb; 25(1):21-7. PubMed ID: 20828605
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice.
He W; Wu JJ; Ning J; Hou J; Xin H; He YQ; Ge GB; Xu W
Toxicol In Vitro; 2015 Oct; 29(7):1569-76. PubMed ID: 26100226
[TBL] [Abstract][Full Text] [Related]
16. Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions.
Salem F; Johnson TN; Barter ZE; Leeder JS; Rostami-Hodjegan A
J Clin Pharmacol; 2013 Aug; 53(8):857-65. PubMed ID: 23720017
[TBL] [Abstract][Full Text] [Related]
17. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone.
Giri P; Naidu S; Patel N; Patel H; Srinivas NR
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):677-688. PubMed ID: 27853934
[TBL] [Abstract][Full Text] [Related]
19. Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.
Gao J; Zhou J; He XP; Zhang YF; Gao N; Tian X; Fang Y; Wen Q; Jia LJ; Jin H; Qiao HL
Oncotarget; 2016 May; 7(19):28612-23. PubMed ID: 27086920
[TBL] [Abstract][Full Text] [Related]
20. Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies.
Ericsson T; Sundell J; Torkelsson A; Hoffmann KJ; Ashton M
Xenobiotica; 2014 Jul; 44(7):615-26. PubMed ID: 24400699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
